Guggenheim Capital LLC Reduces Stake in Cabot Co. (NYSE:CBT)

Guggenheim Capital LLC trimmed its stake in Cabot Co. (NYSE:CBT - Free Report) by 73.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 2,734 shares of the specialty chemicals company's stock after selling 7,752 shares during the period. Guggenheim Capital LLC's holdings in Cabot were worth $250,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Hanlon Investment Management Inc. purchased a new stake in shares of Cabot in the 4th quarter valued at approximately $601,000. Barclays PLC grew its holdings in Cabot by 38.1% during the 4th quarter. Barclays PLC now owns 156,908 shares of the specialty chemicals company's stock worth $14,327,000 after acquiring an additional 43,294 shares in the last quarter. Neuberger Berman Group LLC grew its holdings in Cabot by 1.2% during the 4th quarter. Neuberger Berman Group LLC now owns 18,238 shares of the specialty chemicals company's stock worth $1,665,000 after acquiring an additional 212 shares in the last quarter. LSV Asset Management boosted its holdings in shares of Cabot by 40.5% in the 4th quarter. LSV Asset Management now owns 136,600 shares of the specialty chemicals company's stock valued at $12,473,000 after buying an additional 39,400 shares in the last quarter. Finally, Capital Fund Management S.A. acquired a new position in shares of Cabot in the 4th quarter valued at $2,022,000. 93.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. JPMorgan Chase & Co. lowered their target price on shares of Cabot from $105.00 to $85.00 and set an "underweight" rating for the company in a report on Friday, February 21st. UBS Group lowered their target price on shares of Cabot from $93.00 to $83.00 and set a "neutral" rating for the company in a report on Monday, April 7th. StockNews.com upgraded shares of Cabot from a "hold" rating to a "buy" rating in a report on Thursday, April 17th. Finally, Mizuho lowered their target price on shares of Cabot from $122.00 to $110.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th.

Cabot Stock Down 0.2 %

CBT stock opened at $79.02 on Tuesday. The company has a fifty day moving average price of $81.74 and a 200 day moving average price of $93.34. Cabot Co. has a 12 month low of $73.63 and a 12 month high of $117.46. The company has a market cap of $4.28 billion, a price-to-earnings ratio of 10.49, a price-to-earnings-growth ratio of 0.74 and a beta of 1.04. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.00 and a quick ratio of 1.29.

Cabot (NYSE:CBT - Get Free Report) last announced its quarterly earnings data on Monday, February 3rd. The specialty chemicals company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.74 by $0.02. Cabot had a net margin of 10.60% and a return on equity of 26.79%. Sell-side analysts expect that Cabot Co. will post 7.57 earnings per share for the current year.

Cabot Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.

Want to see what other hedge funds are holding CBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cabot Co. (NYSE:CBT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.